BioMarin Pharmaceutical Inc (BMRN): Price and Financial Metrics

BioMarin Pharmaceutical Inc (BMRN): $90.41

0.06 (-0.07%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add BMRN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#22 of 363

in industry

BMRN Price/Volume Stats

Current price $90.41 52-week high $99.56
Prev. close $90.47 52-week low $76.02
Day low $89.78 Volume 602,321
Day high $91.21 Avg. volume 1,343,550
50-day MA $87.65 Dividend yield N/A
200-day MA $89.01 Market Cap 17.06B

BMRN Stock Price Chart Interactive Chart >


BioMarin Pharmaceutical Inc (BMRN) Company Bio


BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United StatesSouth AmericaAsia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU). (Source:Wikipedia)


BMRN Latest News Stream


Event/Time News Detail
Loading, please wait...

BMRN Latest Social Stream


Loading social stream, please wait...

View Full BMRN Social Stream

Latest BMRN News From Around the Web

Below are the latest news stories about BIOMARIN PHARMACEUTICAL INC that investors may wish to consider to help them evaluate BMRN as an investment opportunity.

BioMarin strikes deal with Elliott, agrees to review business

Under pressure from the activist investor, BioMarin will add more independent directors and set up an operational review committee.

Yahoo | December 21, 2023

BioMarin settles with Elliott, adds 3 independent directors

BioMarin reached a settlement with activist investor Elliott Investment Management where the biotechnology company will add three independent directors to its board and form a committee to review operations. The new Strategic and Operating Review Committee will evaluate the company's business, strategy and operations, financial and capital allocation priorities, and long-term planning and priorities, the company said in a statement. In November, Reuters reported that Elliott owns a stake in BioMarin and had been holding discussions with the company, valued at $18 billion, about possible changes.

Yahoo | December 20, 2023

BioMarin Announces Governance Enhancements and Value Creation Initiatives

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.

Yahoo | December 20, 2023

Insider Sell: EVP, Chief Legal Officer George Davis Sells 13,764 Shares of Biomarin ...

Biomarin Pharmaceutical Inc (NASDAQ:BMRN), a global biotechnology company focused on developing and delivering therapies for rare genetic diseases, has recently witnessed a significant insider sell by one of its top executives.

Yahoo | December 15, 2023

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Key Insights The projected fair value for BioMarin Pharmaceutical is US$193 based on 2 Stage Free Cash Flow to Equity...

Yahoo | December 14, 2023

Read More 'BMRN' Stories Here

BMRN Price Returns

1-mo 6.03%
3-mo -1.99%
6-mo 10.11%
1-year -8.73%
3-year 13.59%
5-year 8.72%
YTD -6.23%
2023 -6.83%
2022 17.14%
2021 0.75%
2020 3.71%
2019 -0.70%

Continue Researching BMRN

Here are a few links from around the web to help you further your research on Biomarin Pharmaceutical Inc's stock as an investment opportunity:

Biomarin Pharmaceutical Inc (BMRN) Stock Price | Nasdaq
Biomarin Pharmaceutical Inc (BMRN) Stock Quote, History and News - Yahoo Finance
Biomarin Pharmaceutical Inc (BMRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!